AUTHOR=Zhu Peng-Chong , Shen Jiayi , Qian Ren-Yi , Xu Jian , Liu Chong , Hu Wu-Ming , Zhang Ying , Lv Ling-Chun 

TITLE=Effect of tanshinone IIA for myocardial ischemia/reperfusion injury in animal model: preclinical evidence and possible mechanisms

JOURNAL=Frontiers in Pharmacology

VOLUME=14

YEAR=2023

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1165212

DOI=10.3389/fphar.2023.1165212

ISSN=1663-9812

ABSTRACT=<p><bold>Introduction:</bold> Tanshinone IIA (Tan IIA), the major active lipophilic ingredient of <italic>Radix Salviae Miltiorrhizae</italic>, exerts various therapeutic effects on the cardiovascular system. We aimed to identify the preclinical evidence and possible mechanisms of Tan IIA as a cardioprotective agent in the treatment of myocardial ischemia/reperfusion injury.</p><p><bold>Methods:</bold> The study quality scores of twenty-eight eligible studies and data analyses were separately assessed using the CAMARADES 10-item checklist and Rev-Man 5.3 software.</p><p><bold>Results:</bold> The study quality score ranged from 3/10 to 7/10 points. The present study provided preliminary preclinical evidence that Tan IIA could significantly decrease the myocardial infarct size, cardiac enzyme activity and troponin levels compared with those in the control group (<italic>p &lt; 0.05</italic>).</p><p><bold>Discussion:</bold> Tan IIA alleviated myocardial I/R injury via antioxidant, anti-inflammatory, anti-apoptosis mechanisms and improved circulation and energy metabolism. Thus, Tan IIA is a promising cardioprotective agent for the treatment of myocardial ischemia/reperfusion injury and should be further investigated in clinical trials.</p>